title: ABT-761 (Abbott).
abstract: Abbott's ABT-761 is a 5-lipoxygenase inhibitor with 8-fold increased potency over Bay-X-1005 and 150-fold over zileuton [171665]. It has a longer duration of action than its closest competitor, ZD-2138 (AstraZeneca), and has entered phase III trials for asthma [224216]. ABT-761 is the follow-up compound for zileuton and, due to its increased potency, requires only once-daily dosing [187700]. ABT-761 has shown excellent oral bioavailability and an extended duration of plasma levels in man, and initial results for a single 200 mg po dose have shown a significant protective effect against exercise- and adenosine-induced bronchoconstriction in asthmatics [215839]. The drug is well tolerated in healthy volunteers and shows linear pharmacokinetics. The pharmacokinetics in children are similar to that of adults.
authors.affiliation: Primary Care Faculty of Medicine, Dunedin School of Medicine, University of Otago, New Zealand. jim.reid@stonebow.otago.ac.nz
authors.forename: J J
authors.initials: JJ
authors.lastname: Reid
mesh_terms: D001249:Asthma / Q000188:drug therapy*; D017326:Clinical Trials, Phase III as Topic; D006801:Humans; D006918:Hydroxyurea / Q000031:analogs & derivatives* / Q000493:pharmacokinetics / Q000494:pharmacology / Q000627:therapeutic use*; D016859:Lipoxygenase Inhibitors / Q000627:therapeutic use*
chemical_list: D016859:Lipoxygenase Inhibitors; C096921:atreleuton; D006918:Hydroxyurea